

- **Name:** Hee Jun Kim
 - **Current Position & Affiliation:** Associate Professor, Section of Medical Oncology-Hematology, Department of Internal Medicine, Chung-Ang University, College of Medicine
 - **Country:** Republic of Korea
-

• Educational Background:

- March 1998 - February 2004: M.D. Chung-Ang University, College of Medicine, Seoul, Korea
- September 2006 - February 2011: Course of Degree of Master in Medicine (Molecular Oncology), Seoul National University College of Medicine, Seoul, Korea
- September 2011-August 2014: Course of Doctor of Philosophy in Medicine (Molecular Oncology), Seoul National University College of Medicine, Seoul, Korea

• Professional Experience:

- March 2004 - February 2005: Internship training, Seoul National University Hospital
- March 2005 - February 2009: Residency training, Dept. of Internal Medicine, Seoul National University Hospital
- March 2009 - February 2011: Clinical Fellowship, Division of Hemato-oncology, Dept. of Internal Medicine, Seoul National University Hospital.
- March 2011 –now: Associate Professor, Division of Hemato-oncology, Dept. of Internal Medicine, Chung-Ang University Hospital.
- March 2020 - February 2021: Research Fellow at Division of Internal Medicine, Department of Neuro-Oncology, UCSF

• Professional Organizations:

- Member of ASCO, ESMO
- Member of KCSG, KSMO. KASCC

• Main Scientific Publications:

1. Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase II Trial (KCSG-BR 15-10)
Soohyeon Lee, Seock-Ah Im, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee, **Hee-Jun Kim**, Han Jo Kim, Jong In Lee, Su-Jin Koh, Yeon Hee Park
Cancers (Basel) 2020 Nov; 12(11): 3265. Published online 2020 Nov 5. doi:
10.3390/cancers12113265

2. Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR10-13)
Ju Won Kim, Soohyeon Lee, Hye Sook Kim, Yoon Ji Choi, Jinho Yoo, Keon Uk Park, Seok Yun Kang, Yeon Hee Park, Kyung Hae Jung, Jin-Hee Ahn, Ho-suk Oh, In Sil Choi, **Hee Jun Kim**, Kyung-Hun Lee, Suee Lee, Jae Hong Seo, In Hae Park, Kyung Eun Lee, Ho Young Kim, Kyong Hwa Park
3. Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16–12)
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, **Hee-Jun Kim**, Yong Bae Kim, Jee Suk Chang, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim
Breast. 2020 Feb; 49: 41–47. Published online 2019 Oct 22. doi: 10.1016/j.breast.2019.10.007
4. TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
Jin Won Kim, Ahrum Min, Seock-Ah Im, Hyemin Jang, Yu Jin Kim, **Hee-Jun Kim**, Kyung-Hun Lee, Tae-Yong Kim, Keun Wook Lee, Do-Youn Oh, Jee-Hyun Kim, Yung-Jue Bang
Cancers (Basel) 2020 Feb; 12(2): 334. Published online 2020 Feb 3. doi: 10.3390/cancers12020334
5. Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03
Woo Kyun Bae, Hyo Jin Lee, Se Hoon Park, Jung Hoon Kim, **Hee Jun Kim**, Chi Hoon Maeng, Inkeun Park, Byeong Seok Sohn, Jung A. Kim, Kyung Hee Lee, Do Hyoung Lim, Hyun Chang, Sung Min Kim, Ho Young Kim, Hunho Song, Seungtaek Lim, Jae Ho Byun, Hyun Ae Jung
Cancer Med. 2019 Sep; 8(12): 5431–5437. Published online 2019 Jul 29. doi: 10.1002/cam4.2446
6. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH, Kim TY, Kim GM, Kang SY, Park IH, Kim JH, Lee KE, Ahn HK, Lee MH, Kim HJ, Kim HJ, Lee JI, Koh SJ, Kim JY, Lee KH, Sohn J, Kim SB, Ahn JS, Im YH, Jung KH, Im SA; Korean Cancer Study Group (KCSG)
Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30565-0
7. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16)
Park I, Kim BS, Lim HY, **Kim HJ**, Lee HJ, Choi YJ, Park KH, Lee KH, Yoon S, Hong B, Hong JH, Ahn H, Lee JL.
Eur J Cancer. 2019 Oct 24. pii: S0959-8049(19)30727-0
8. Incidence, Risk Factors, and Clinical Outcomes of Acute Kidney Injury Caused by Palliative Chemotherapy in Lung Cancer.
Park SE, Hwang JH, Choi JH, Kim SH, Choi JC, Jang JS, **Kim HJ**, Park SW, Seok JW, Hwang IG
J Cancer. 2019 Aug 29;10(22):5332-5338.
9. Mortality reduction with physical activity in patients with and without cardiovascular disease.
Jeong SW, Kim SH, Kang SH, **Kim HJ**, Yoon CH, Youn TJ, Chae IH
Eur Heart J. 2019 Sep 1. pii: ehz564. doi: 10.1093
10. A Mobile Game for Patients With Breast Cancer for Chemotherapy Self-Management and Quality-of-Life Improvement: Randomized Controlled Trial
Kim HJ, Kim SM, Shin H, Jang JS, Kim YI, Han DH.
J Med Internet Res. 2018 Oct 29;20(10):e273
11. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA, Noh DY.
Cancer Sci. 2015 Jan;106(1):86-93